Technical Analysis for CALC - CalciMedica, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Sell Signal | Bearish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Jack-in-the-Box Bullish | Bullish Swing Setup | 3.02% | |
| Upper Bollinger Band Walk | Strength | 3.02% | |
| Inside Day | Range Contraction | 3.02% |
| Alert | Time |
|---|---|
| Up 5% | about 3 hours ago |
| 60 Minute Opening Range Breakout | about 6 hours ago |
| Jack-in-the-Box Bullish Entry | about 6 hours ago |
| Rose Above Previous Day's High | about 6 hours ago |
| Gap Up Partially Closed | about 8 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/13/2024
CalciMedica, Inc. Description
CalciMedica is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica’s proprietary technology targets the inhibition of calcium release-activated calcium (CRAC) channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are currently no approved therapies. CalciMedica’s lead product candidate Auxora, a proprietary, intravenous-formulated CRAC channel inhibitor, has demonstrated positive and consistent clinical results in four completed efficacy clinical trials. Auxora is in development for acute pancreatitis and asparaginase-associated pancreatitis. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Medication Inflammatory Diseases Abdominal Pain Pancreatitis Acute Pancreatitis Asparaginase
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.82 |
| 52 Week Low | 1.0 |
| Average Volume | 22,091 |
| 200-Day Moving Average | 3.65 |
| 50-Day Moving Average | 4.34 |
| 20-Day Moving Average | 4.46 |
| 10-Day Moving Average | 4.64 |
| Average True Range | 0.41 |
| RSI (14) | 69.51 |
| ADX | 21.38 |
| +DI | 33.92 |
| -DI | 11.10 |
| Chandelier Exit (Long, 3 ATRs) | 4.56 |
| Chandelier Exit (Short, 3 ATRs) | 5.11 |
| Upper Bollinger Bands | 5.33 |
| Lower Bollinger Band | 3.59 |
| Percent B (%b) | 1.07 |
| BandWidth | 39.08 |
| MACD Line | 0.23 |
| MACD Signal Line | 0.09 |
| MACD Histogram | 0.1398 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.83 | ||||
| Resistance 3 (R3) | 5.83 | 5.70 | 5.76 | ||
| Resistance 2 (R2) | 5.70 | 5.61 | 5.70 | 5.74 | |
| Resistance 1 (R1) | 5.58 | 5.55 | 5.52 | 5.58 | 5.72 |
| Pivot Point | 5.45 | 5.45 | 5.42 | 5.45 | 5.45 |
| Support 1 (S1) | 5.33 | 5.36 | 5.26 | 5.32 | 5.18 |
| Support 2 (S2) | 5.20 | 5.30 | 5.20 | 5.16 | |
| Support 3 (S3) | 5.08 | 5.20 | 5.14 | ||
| Support 4 (S4) | 5.07 |
